Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma

淋巴瘤中人内源性逆转录病毒、HIV 和 EBV 之间的监管串扰

基本信息

  • 批准号:
    10616708
  • 负责人:
  • 金额:
    $ 117.81万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2021
  • 资助国家:
    美国
  • 起止时间:
    2021-05-01 至 2026-04-30
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT Approximately 8% of the human genome is composed of sequences directly derived from germline infections of diverse retroviruses, which have accumulated over the past ~100 million years of mammalian evolution. None of these human endogenous retroviruses (HERVs) are known to represent fully functional retroviruses, but most have retained noncoding regulatory sequences that can control expression of cellular genes acting as promoters or enhancers, and some still encode proteins with various functional activities. While HERV sequences are often ignored as merely inconsequential ‘junk’ DNA, there is evidence that a subset of these elements play crucial roles in human physiology and disease, including cancer. Our previous work, as well as that of others, have shown that both HIV and EBV infections activate certain HERV families that have oncogenic activities, and our preliminary data reveal an overlap between these elements. Given that diffuse large B cell lymphomas (DBCL) are frequently associated with EBV infection in people living with HIV, we hypothesize that there is a complex intercellular regulatory crosstalk between AIDS related (AR)-DLBCL, HIV-infected T cells and the tissue microenvironment, that is in part mediated by a specific subset of HERVs and their derived products that are synergistically activated and promote oncogenesis. We will study DLBCL obtained from patients with or without EBV (and with or without HIV) from the USA and Brazil, which will be comprehensively characterized pathologically and molecularly using single-cell genomics and spatial transcriptomics. We will analyze these data using computational tools we have tailored to profile and link HERV and gene expression. Furthermore, we will establish in vitro models to dissect with precision the functional impact of HERV on the crosstalk between T cells infected by HIV and B cells with or without EBV. We will also determine if differential HERV expression creates neoantigenic epitopes, a feature that can be exploited for immunotherapy. This will be accomplished through three specific aims: 1) Characterize and profile HERV regulation and expression within single cells in DLBCL and AR-DLBCL; 2) Establish in vitro models to dissect the interaction between cellular and endogenous and exogenous viruses in AR-DLBCL; 3) Identification of neo-antigenic HERV epitopes in DLBCL and ascertain if cloned HERV specific CTL can lyse lymphoma cells in vitro. Our team consists of specialists in lymphoma biology and medicine, transposable elements and HERVs, HIV and EBV viral immunology. Together, we will generate understandings of how HERVs contribute to the pathogenesis of AR-DLCBL, and identify new antigenic targets for novel therapies.
项目摘要/摘要 大约8%的人类基因组由直接来自生殖系感染的序列组成 多种多样的逆转录病毒,在过去1亿年的哺乳动物进化中积累起来。无 已知这些人类内源性逆转录病毒(HERV)代表全功能逆转录病毒,但大多数 保留了非编码调控序列,可以控制作为启动子的细胞基因的表达 或增强剂,其中一些仍然编码具有各种功能活性的蛋白质。而Herv序列通常是 被忽略的仅仅是无关紧要的‘垃圾’DNA,有证据表明,这些元素的子集起着至关重要的作用 在人类生理和疾病方面的作用,包括癌症。我们之前的工作以及其他人的工作都有 显示HIV和EBV感染都会激活某些具有致癌活性的Herv家族,而我们的 初步数据显示,这些元素之间存在重叠。鉴于弥漫性大B细胞淋巴瘤(DBCL) 在艾滋病毒携带者中经常与EBV感染有关,我们假设有一个复杂的 艾滋病相关(AR)-DLBCL、HIV感染的T细胞和组织之间的细胞间调节串扰 微环境,部分由HERV及其衍生产品的特定子集介导,这些HERV及其衍生产品 协同激活,促进肿瘤发生。我们将研究从患有或不患有DLBCL的患者获得的DLBCL 来自美国和巴西的EBV(以及是否携带艾滋病毒),将全面描述其特征 在病理学和分子水平上使用单细胞基因组学和空间转录组学。我们将对这些数据进行分析 使用我们量身定做的计算工具来描述和连接HERV和基因表达。此外,我们还将 建立体外模型精确分析HERV对T细胞间串扰的功能影响 感染HIV和B细胞,携带或不携带EBV。我们还将确定差分Herv表达式是否会创建 新的抗原表位,这一特征可用于免疫治疗。这将通过以下方式实现 3个特定目标:1)DLBCL单细胞内HERV调控和表达的特征和特征 和AR-DLBCL;2)建立体外模型,解剖细胞与内源性和 外源病毒在AR-DLBCL中的表达;3)DLBCL中新的抗原性HERV表位的鉴定 克隆的HERV特异性CTL对淋巴瘤细胞具有体外杀伤作用。我们的团队由淋巴瘤生物学专家组成 以及医学、转座子和HERV、艾滋病毒和EBV病毒免疫学。共同努力,我们将创造 了解HERV在AR-DLCBL发病机制中的作用,寻找新的抗原靶点 寻找新的疗法。

项目成果

期刊论文数量(5)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Ribosomal profiling of human endogenous retroviruses in healthy tissues.
  • DOI:
    10.1186/s12864-023-09909-x
  • 发表时间:
    2024-01-02
  • 期刊:
  • 影响因子:
    4.4
  • 作者:
    Dopkins, Nicholas;Singh, Bhavya;Michael, Stephanie;Zhang, Panpan;Marston, Jez L.;Fei, Tongyi;Singh, Manvendra;Feschotte, Cedric;Collins, Nicholas;Bendall, Matthew L.;Nixon, Douglas F.
  • 通讯作者:
    Nixon, Douglas F.
3D chromosomal architecture in germinal center B cells and its alterations in lymphomagenesis.
Endogenous Reverse Transcriptase Inhibition Attenuates TLR5-Mediated Inflammation.
  • DOI:
    10.1128/mbio.03280-22
  • 发表时间:
    2023-02-28
  • 期刊:
  • 影响因子:
    6.4
  • 作者:
  • 通讯作者:
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ETHEL CESARMAN其他文献

ETHEL CESARMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ETHEL CESARMAN', 18)}}的其他基金

Tri-I Stimulating Access to Research in Residency program (Tri-I StARR - NIAID)
Tri-I 促进住院医师研究项目 (Tri-I StARR - NIAID)
  • 批准号:
    10592130
  • 财政年份:
    2023
  • 资助金额:
    $ 117.81万
  • 项目类别:
Next-Gen Oncopathology Program
下一代肿瘤病理学计划
  • 批准号:
    10676213
  • 财政年份:
    2022
  • 资助金额:
    $ 117.81万
  • 项目类别:
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE
使用 KS-COMPLETE 对撒哈拉以南非洲地区的卡波西肉瘤进行快速样本到答案诊断
  • 批准号:
    10416778
  • 财政年份:
    2022
  • 资助金额:
    $ 117.81万
  • 项目类别:
Rapid Sample-to-Answer Diagnosis of Kaposi's Sarcoma Across Sub-Saharan Africa using KS-COMPLETE
使用 KS-COMPLETE 对撒哈拉以南非洲地区的卡波西肉瘤进行快速样本到答案诊断
  • 批准号:
    10642906
  • 财政年份:
    2022
  • 资助金额:
    $ 117.81万
  • 项目类别:
B cell determinants of EBV latency
EBV 潜伏期的 B 细胞决定因素
  • 批准号:
    10541734
  • 财政年份:
    2022
  • 资助金额:
    $ 117.81万
  • 项目类别:
B cell determinants of EBV latency
EBV 潜伏期的 B 细胞决定因素
  • 批准号:
    10701826
  • 财政年份:
    2022
  • 资助金额:
    $ 117.81万
  • 项目类别:
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
淋巴瘤中人内源性逆转录病毒、HIV 和 EBV 之间的监管串扰
  • 批准号:
    10228431
  • 财政年份:
    2021
  • 资助金额:
    $ 117.81万
  • 项目类别:
Regulatory Crosstalk Between Human Endogenous Retroviruses, HIV, and EBV, in Lymphoma
淋巴瘤中人内源性逆转录病毒、HIV 和 EBV 之间的监管串扰
  • 批准号:
    10398963
  • 财政年份:
    2021
  • 资助金额:
    $ 117.81万
  • 项目类别:
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment
(PQ 6) KSHV 肿瘤发生和 KS 免疫环境的新模型
  • 批准号:
    10737765
  • 财政年份:
    2020
  • 资助金额:
    $ 117.81万
  • 项目类别:
(PQ 6) New Models of KSHV Oncogenesis and KS Immune Environment
(PQ 6) KSHV 肿瘤发生和 KS 免疫环境的新模型
  • 批准号:
    10397107
  • 财政年份:
    2020
  • 资助金额:
    $ 117.81万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了